- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S1312||Streptozotocin (STZ)||53 mg/mL||53 mg/mL||<1 mg/mL|
|S1692||Busulfan||<1 mg/mL||49 mg/mL||<1 mg/mL|
|S2057||Cyclophosphamide Monohydrate||7 mg/mL||55 mg/mL||<1 mg/mL|
|S1278||Altretamine||<1 mg/mL||15 mg/mL||33 mg/mL|
|S7829||CB1954||<1 mg/mL||50 mg/mL||<1 mg/mL|
|S8266||Melphalan||<1 mg/mL||10 mg/mL||<1 mg/mL|
- DNA alkylator Inhibitors (6)
|Catalog No.||Information||Product Use Citations||Product Validations|
Streptozotocin is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent.
Effect of telmisartan and other treatments on (a) nitric oxide, (b) serum cortisol level. Data is expressed as mean ± SEM (n = 6). Statistical significances were determined using one way ANOVA followed by dunnetts post hoc test. ###p < 0.001 as compared with normal, *p < 0.05, *p < 0.01, ***p < 0.001 as compared to STZ control. TMS: telmisartan, MET: metformin, FLX: fluoxetine. The figure in parenthesis indicates the dose in mg/kg po.
Busulfan is a cell cycle non-specific alkylating antineoplastic agent.
Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Conditional patched mutant tumor cells were treated with increasing concentrations cyclophosphamide (D), alone or in combination with 10 nmol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours. Data represent means of triplicate samples ± SEM.
Altretamine is an anti-neoplastic agent.
CB1954(Tretazicar) is a anticancer prodrug that is converted in the presence of the enzyme NQO2 and co-substrate caricotamide ( EP-0152R) (EP) into a potent cytotoxic bifunctional alkylating agent. It can be activated by NAD(P)H quinone oxidoreductase 2.
Melphalan is a phenylalanine derivative of nitrogen mustard with antineoplastic activity.
(C)ChIP analysis using a SIRT6 specific antibody to detect SIRT6 recruitment at Alu sequences after DNA damage triggered by doxorubicin (1μM) or melphalan (100μM), with or without pretreatment with OSS_128167 (200 μM). Occupancy at Alu sites is shown relative to background signal with IgG control antibody. n= 3 independent experiments. Data are presented as the mean ± S.D. *p=0.01; ** p=0.003 (Student's t test) (D) ChIP analysis to detect H3K56 acetylation at DNA damage sites in SIRT6 WT and KD MM cells upon genotoxic stress. Antibody to acetylated H3K56 was used, and levels are shown relative to the background signal with IgG control antibody. n= 4 independent experiments. Data are presented as the mean ± S.D. ****p<0.0001 (unpaired t test)